KH
Knight Therapeutics Inc.
KHTRF · OTC
$7.24 +1.26% (+$0.09)
1M +2.14%
Market Cap $982.2M
P/E Ratio 66.87x
Div. Yield -
ROE 1.88%
Bulios Fair Price
$5.32
26.5% downside
Current Price
$7.24
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KHTRF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
67 /100
Cheap P/E 66.87x
EV/EBITDA 11.34x
P/S 1.79x
Growth
82 /100
Growing Rev. growth 15.28%
FCF growth 67.03%
Book val. growth 2.45%
Profitability
56 /100
Moderate Gross margin 39.34%
Net margin 2.68%
Op. margin 4.82%
Quality
14 /100
Poor ROIC 2.09%
ROE 1.88%
ROA 1.41%
Debt
84 /100
Low Debt/Equity 0.04x
Current ratio 2.28x
Int. coverage 1.56x
Stability
31 /100
Unstable Beta 0.05x
Rev. volatility 5.04%
EPS volatility 183.52%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KHTRF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Samira Sakhia
Employees
830
Headquarters
Montreal
Upcoming events
05 NOV
Earnings
Upcoming earnings report